WA
BBIO icon

WPG Advisers’s BridgeBio Pharma BBIO Stock Holding History

WPG Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Buy
161
+4
+3% +$290 0.01% 616
2025
Q4 		$12K Buy
157
+145
+1,208% +$9.52K 0.01% 652
2025
Q3 		$623 Buy
+12
New +$585 ﹤0.01% 1335

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WPG Advisers's BBIO Position: Q1 2026 in Review

WPG Advisers increased its BridgeBio Pharma (BBIO) stake by 2.5% in Q1 2026, buying an estimated $290 and bringing the position to 161 shares worth $12K. The position accounts for 0.01% of the portfolio, ranked #616.

WPG Advisers first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $12K in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • WPG Advisers held 161 shares of BridgeBio Pharma worth $12K as of Q1 2026.
  • WPG Advisers bought 4 BridgeBio Pharma shares in Q1 2026, an estimated $290.
  • BridgeBio Pharma made up 0.01% of WPG Advisers's portfolio in Q1 2026, its #616 holding.
  • WPG Advisers first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • WPG Advisers's BridgeBio Pharma position peaked at $12K in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on WPG Advisers's 13F filing for Q1 2026, filed 30 Apr 2026.